Drug–Drug Interaction Profile of the Fixed-Dose Combination Tablet Regimen Ledipasvir/Sofosbuvir
出版年份 2018 全文链接
标题
Drug–Drug Interaction Profile of the Fixed-Dose Combination Tablet Regimen Ledipasvir/Sofosbuvir
作者
关键词
-
出版物
CLINICAL PHARMACOKINETICS
Volume -, Issue -, Pages -
出版商
Springer Nature
发表日期
2018-04-11
DOI
10.1007/s40262-018-0654-5
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Impact of anti-HCV direct antiviral agents on graft function and immunosuppressive drug levels in kidney transplant recipients: a call to attention in the mid-term follow-up in a single-center cohort study
- (2018) Mario Fernández-Ruiz et al. TRANSPLANT INTERNATIONAL
- Decreased tacrolimus plasma concentrations during HCV therapy: a drug–drug interaction or is there an alternative explanation?
- (2017) E.J. Smolders et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- Clinical Pharmacokinetics and Pharmacodynamics of Ledipasvir/Sofosbuvir, a Fixed-Dose Combination Tablet for the Treatment of Hepatitis C
- (2016) Polina German et al. CLINICAL PHARMACOKINETICS
- Pharmacokinetic, Pharmacodynamic, and Drug-Interaction Profile of the Hepatitis C Virus NS5B Polymerase Inhibitor Sofosbuvir
- (2015) Brian J. Kirby et al. CLINICAL PHARMACOKINETICS
- Ledipasvir and Sofosbuvir for HCV in Patients Coinfected with HIV-1
- (2015) Susanna Naggie et al. NEW ENGLAND JOURNAL OF MEDICINE
- Lack of a clinically important pharmacokinetic interaction between sofosbuvir or ledipasvir and hormonal oral contraceptives norgestimate/ethinyl estradiol in HCV-Uninfected female subjects
- (2014) P. German et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Ledipasvir and Sofosbuvir for Untreated HCV Genotype 1 Infection
- (2014) Nezam Afdhal et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ledipasvir and Sofosbuvir for Previously Treated HCV Genotype 1 Infection
- (2014) Nezam Afdhal et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ledipasvir and Sofosbuvir for 8 or 12 Weeks for Chronic HCV without Cirrhosis
- (2014) Kris V. Kowdley et al. NEW ENGLAND JOURNAL OF MEDICINE
- HIV, Age, and the Severity of Hepatitis C Virus–Related Liver Disease
- (2013) Gregory D. Kirk et al. ANNALS OF INTERNAL MEDICINE
- Treatment of Hepatitis C Virus Infection Among People Who Are Actively Injecting Drugs: A Systematic Review and Meta-analysis
- (2013) Esther J. Aspinall et al. CLINICAL INFECTIOUS DISEASES
- Antiviral Activity, Safety, and Pharmacokinetics/Pharmacodynamics of Tenofovir Alafenamide as 10-Day Monotherapy in HIV-1–Positive Adults
- (2013) Peter J. Ruane et al. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
- Role of CYP2B6 in Stereoselective Human Methadone Metabolism
- (2009) Rheem A. Totah et al. ANESTHESIOLOGY
- Effect of Tipranavir-Ritonavir on Pharmacokinetics of Raltegravir
- (2009) W. D. Hanley et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Meta‐Analysis: Increased Mortality Associated with Hepatitis C in HIV‐Infected Persons Is Unrelated to HIV Disease Progression
- (2009) Ting‐Yi Chen et al. CLINICAL INFECTIOUS DISEASES
- Effects of a concomitant single oral dose of rifampicin on the pharmacokinetics of pravastatin in a two-phase, randomized, single-blind, placebo-controlled, crossover study in healthy Chinese male subjects
- (2009) Sheng Deng et al. CLINICAL THERAPEUTICS
- Minimal Effects of Ritonavir and Efavirenz on the Pharmacokinetics of Raltegravir
- (2008) M. Iwamoto et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Mechanism of Ritonavir Changes in Methadone Pharmacokinetics and Pharmacodynamics: I. Evidence Against CYP3A Mediation of Methadone Clearance
- (2008) ED Kharasch et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Estimation of stage-specific fibrosis progression rates in chronic hepatitis C virus infection: A meta-analysis and meta-regression
- (2008) Hla-Hla Thein et al. HEPATOLOGY
- Liver Fibrosis during an Outbreak of Acute Hepatitis C Virus Infection in HIV‐Infected Men: A Prospective Cohort Study
- (2008) Daniel S. Fierer et al. JOURNAL OF INFECTIOUS DISEASES
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now